An alcohol interaction study of Hydromorphone extended-release for evaluation of abuse-deterrent capabilities

Trial Profile

An alcohol interaction study of Hydromorphone extended-release for evaluation of abuse-deterrent capabilities

Planning
Phase of Trial: Phase I

Latest Information Update: 03 Jan 2017

At a glance

  • Drugs Hydromorphone (Primary)
  • Indications Pain
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 03 Jan 2017 This trial was planned by Flamel Technologies. The company has completed cross-border merger and became Avadel Pharmaceuticals plc, according to a Flamel Technologies media release.
    • 13 Sep 2016 New trial record
    • 08 Aug 2016 According to a Flamel Technologies media release, following guidance from FDA the company will be conducting an alcohol interaction study in the second half of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top